A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene.

The ATM-p53 pathway plays an important role in the biology of chronic lymphocytic leukemia (CLL). Its functional integrity can be probed by exposing CLL cells to ionizing radiation (IR) and measuring levels of p53 protein and one of its transcriptional targets, the cyclin-dependent kinase inhibitor p21. We have previously identified two abnormal p53/p21 response patterns associated with inactivating mutations of TP53 and ATM, respectively. Here, we describe a third abnormal response pattern characterized by failure of p21 protein accumulation despite a normal p53 protein response. This so-called "type C" response was detected in 10.6% of unselected patients and was associated with resistance of CLL cells to p53-dependent killing by IR, with the clinically more aggressive variant of CLL characterized by unmutated immunoglobulin heavy-chain genes and with a single nucleotide polymorphism at codon 31 of the p21 gene in which Ser is replaced by Arg. CLL samples with this allelic variant displayed impaired IR-induced up-regulation of total p21 mRNA and did not express the Arg-encoding transcript, except in those cases harboring an additional single nucleotide polymorphism (T instead of C) in the 3'-untranslated region of the same p21 allele. Our data provide new insight into the importance of p21 in CLL biology.

[1]  W. R. Bishop,et al.  Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy. , 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[2]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[3]  C. Purdie,et al.  Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.

[4]  S. Kuersten,et al.  The power of the 3′ UTR: translational control and development , 2003, Nature Reviews Genetics.

[5]  C. Salvarani,et al.  The codon 72 polymorphic variants of p53 in Italian rheumatoid arthritis patients. , 2007, Clinical and experimental rheumatology.

[6]  D. Lane,et al.  Cancer. p53, guardian of the genome. , 1992, Nature.

[7]  John C Reed,et al.  Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Peller Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response. , 1998, Seminars in cancer biology.

[9]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[10]  A. Brookes The essence of SNPs. , 1999, Gene.

[11]  A. Pettitt,et al.  p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. , 2001, Blood.

[12]  M. Gordon Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication , 2009 .

[13]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[14]  M. Murphy,et al.  Polymorphisms in the p53 pathway , 2006, Oncogene.

[15]  B. Quesnel,et al.  p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies , 1994 .

[16]  I. Bleiweiss,et al.  p53 haplotype determination in breast cancer. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[17]  D. Christiani,et al.  P53 (codon 72) and P21 (codon 31) polymorphisms alter in vivo mRNA expression of p21. , 2003, Lung cancer.

[18]  A. Pettitt,et al.  Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia , 2006, Leukemia.

[19]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[20]  A. Pettitt,et al.  Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia , 2004, British journal of haematology.

[21]  Miranda Thomas,et al.  Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically , 1999, Molecular and Cellular Biology.

[22]  G. Dotto,et al.  p21(WAF1/Cip1): more than a break to the cell cycle? , 2000, Biochimica et biophysica acta.

[23]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[24]  J. Vijg,et al.  SNP discovery in associating genetic variation with human disease phenotypes. , 2005, Mutation research.

[25]  O. Pereira-smith,et al.  Competition of CUGBP1 and calreticulin for the regulation of p21 translation determines cell fate , 2004, The EMBO journal.

[26]  Z. Livneh,et al.  p53 and p21 regulate error-prone DNA repair to yield a lower mutation load. , 2006, Molecular cell.

[27]  J. Lotem,et al.  Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. , 1993, Blood.

[28]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[29]  H. Lincet,et al.  The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. , 2000, Cancer letters.

[30]  Emili Montserrat,et al.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.

[31]  Jong-Yeon Shin,et al.  p21WAF/CIP1/SDI1 is upregulated due to increased mRNA stability during hydroxyurea-induced senescence of human fibroblasts , 2005, Mechanisms of Ageing and Development.

[32]  Adrian Wiestner,et al.  ZAP-70 expression and prognosis in chronic lymphocytic leukaemia , 2004, The Lancet.

[33]  V. Rotter,et al.  TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance , 2003, Human mutation.

[34]  J. Siedlecki,et al.  Regulatory functions of 3'UTRs. , 2001, Biochemical and biophysical research communications.

[35]  A Benner,et al.  p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.

[36]  R. Ralhan,et al.  Novel polymorphism in p21waf1/cip1 cyclin dependent kinase inhibitor gene: association with human esophageal cancer , 2000, Oncogene.

[37]  A. Gartel The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis. , 2005, Leukemia research.

[38]  D. Oscier,et al.  Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. , 2002, Blood.

[39]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[40]  N. Saitou,et al.  Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. , 2003, Human molecular genetics.

[41]  E. Newcomb,et al.  p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression , 1993 .

[42]  P. V. D. van den Berk,et al.  A/T mutagenesis in hypermutated immunoglobulin genes strongly depends on PCNAK164 modification , 2007, The Journal of experimental medicine.

[43]  A. Pettitt,et al.  High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment. , 2003, Blood.

[44]  A. Fritscher-Ravens Endoscopic ultrasound evaluation in the diagnosis and staging of lung cancer. , 2003, Lung cancer.

[45]  C. Lawrence,et al.  An update on the role of translesion synthesis DNA polymerases in Ig hypermutation. , 2005, Trends in immunology.

[46]  P. Loehrer Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial , 2008 .

[47]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[48]  R. Birgander,et al.  Is p53 polymorphism maintained by natural selection? , 1994, Human heredity.

[49]  Axel Benner,et al.  Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. , 2002, Blood.

[50]  E. Tajara,et al.  Analysis of CDKN1A polymorphisms: markers of cancer susceptibility? , 2003, Cancer genetics and cytogenetics.

[51]  M. Miura,et al.  Resistance to Fas-mediated apoptosis: activation of Caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP , 1998, Oncogene.

[52]  A. Pettitt,et al.  Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. , 2002, Blood.

[53]  Patrick Dumont,et al.  The Codon 47 Polymorphism in p53 Is Functionally Significant*[boxs] , 2005, Journal of Biological Chemistry.

[54]  N. Park,et al.  p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. , 2004, Gynecologic oncology.

[55]  T. Möröy,et al.  ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia , 2003, Leukemia.

[56]  N. Chiorazzi,et al.  mechanisms of disease Chronic Lymphocytic Leukemia , 2010 .

[57]  P. D. Lee,et al.  Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. , 1995, Human molecular genetics.

[58]  G. Brittinger,et al.  Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. , 2005, Blood.

[59]  Michael A. Crawford,et al.  Acknowledgement to the 2000 Reviewers , 2000, Annals of Nutrition and Metabolism.

[60]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.